Metformin IN Asthma for Overweight and Obese Individuals (MINA)

Description

This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.

Conditions

Asthma, Asthma Chronic, Overweight and Obesity

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.

Metformin IN Asthma for Overweight and Obese Individuals (MINA)

Metformin IN Asthma for Overweight and Obese Individuals (MINA)

Condition
Asthma
Intervention / Treatment

-

Contacts and Locations

Baltimore

Johns Hopkins University, Baltimore, Maryland, United States, 21224

Houston

Baylor College of Medicine, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Physician-diagnosed asthma on maintenance therapy
  • * Not well-controlled asthma (ACT score \<20, or at least one asthma exacerbation requiring corticosteroids in the prior 12 months)
  • * Overweight or obesity: Body mass index ≥25kg/m2
  • * Adult: Age ≥18
  • * Currently pregnant, expect to become pregnant in the next 6 months or are currently breastfeeding
  • * Major cardiovascular disease: heart failure, heart attack or stroke within the last 6 months
  • * Other chronic lung disease, inclusive of chronic obstructive pulmonary disease, bronchiectasis, interstitial lung disease, pulmonary fibrosis
  • * Active smoking or former smoker with ≥20 pack-year smoking history
  • * Chronic kidney disease: estimated glomerular filtration rate ≤60 mL/min/1.73 m2
  • * Heavy alcohol use: in a typical week, 8 or more drinks for a woman or 15 or more drinks for a man
  • * Liver disease: elevation in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2x the upper limit of normal or prior diagnosis of liver disease
  • * Anemia: hemoglobin \< 13 g/dl in males and hemoglobin \< 11 g/dl in females
  • * Taking Glucagon Like Peptide 1(GLP-1) medications for weight loss
  • * Diabetes (Hemoglobin A1C ≥ 6.5% or taking metformin or other medications used to treat diabetes)
  • * Participation in any other clinical trial (observational studies are permitted)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Johns Hopkins University,

Meredith C McCormack, M.D., M.H.S., PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Tianshi D Wu, M.D., M.H.S., PRINCIPAL_INVESTIGATOR, Baylor College of Medicine

Study Record Dates

2028-12-31